Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (71)

1

First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO

enthalten in: Aktuelle Urologie | 2023

2

Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma : final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study Group

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2020

von Nieder, C.

3

Clinical implications of the PORTEC-3 trial for the treatment of high-risk endometrial cancer

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2020

von Waltar, T. | Marnitz, S.

4

Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)

enthalten in: Der Internist | 2017

von Alten, R. | Nitschmann, S.

5

First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Ohlmann, C. | Gschwend, J. | +1

6

Adjuvant radiotherapy for lymph-node-positive prostate cancer with low tumor load after radical prostatectomy : Multicenter randomized phase III study of the effect of adjuvant radiotherapy in patients with prostate cancer with or without a positive margin after radical prostatectomy (RP) and lymph node metastasis with low tumor load (micrometastases, ≤ 2 lymph node macrometastases). ART-2 - study AP 61/10 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Bartkowiak, D.

7

Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2017

von Rödel, C. | Fokas, E.

8

Time interval between neoadjuvant radiochemotherapy and surgery in rectal cancer : No impact on the pathologic complete response rate?

enthalten in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al | 2017

von Gani, C. | Zips, D.

9

Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Retz, M. | Albers, P.

10

enthalten in: Medizinische Monatsschrift fur Pharmazeuten | 2016

von Ecker-Schlipf, B.

1
2
3
4
5
6
7
8
Nächster »
[8]